Early Safety Assessment
Declining industrial productivity has forced companies to urgently address the areas of drug development that are most likely to lead to the failure of a new compound. Drug discovery researchers need strategies and tools that support the earlier termination of drug candidates that are likely to be toxic in humans.
As a result, many drug discovery labs have begun to implement new predictive technologies that can facilitate earlier termination of potentially unsuccessful compounds, including emerging approaches in key areas such as hepatotoxicity, nephrotoxicity, and cardiotoxicity.
The US Food & Drug Administration (FDA) is highly focused on the safety of new drugs. In fact, the FDA requires that the activity of novel agents on hERG, a surrogate marker for potential cardiac toxicity, be evaluated. Inhibition of cardiac hERG channels has been identified as the mechanism underlying the toxicity of several therapeutic agents.
In order to be used in a cost-effective manner for screening, hERG assays, as well as other assays that generate data relevant to predicting safety of drug candidates, must be of high quality, repeatable, and reliable.
Molecular Devices provides automated electrophysiology and high-content analysis systems as well as a range of validation and compliance tools that support screening assays to enable early termination of drug candidates with likely safety issues. Please use the links below to learn more.